Will the recent momentum be cut short following the biotech's Feb. 10 earnings release, or will it continue? Over the past ...

GIlead Sciences (GILD) stock is trading at record highs after announcing a top- and bottom-line beat for the fourth quarter ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.

They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...

Family and consumer sciences professionals shape lives daily, support communities and quietly power some of the country’s most essential industries. For years, the value of that work has been clear to ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Exact Sciences announced on Wednesday that it acquired the rights to a blood-based ...

On 20 January 2026, Ropes & Gray’s Global Life Sciences Regulatory & Compliance team hosted the “Life Sciences Regulatory Outlook 2026” webinar.